Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Key Market Drivers
Increasing Prevalence of Influenza and Respiratory Disorders
The rising incidence of influenza and other respiratory conditions is a major driver of the influenza vaccine market in India. Chronic respiratory conditions such as asthma and COPD increase vulnerability to influenza-related complications, prompting the need for preventive vaccination. Data from India’s Ministry of Health indicates that 28 million people suffer from asthma and 17 million from COPD, making a significant portion of the population susceptible to severe flu outcomes. Seasonal influenza outbreaks, including subtypes like H1N1 and H3N2, continue to pose public health challenges. As of March 2023, over 3,000 lab-confirmed cases of various flu subtypes were recorded, while over 9,000 H1N1 cases were reported in 2024, resulting in 178 fatalities by July. These figures underscore the critical need for widespread immunization to mitigate health risks and hospitalizations associated with influenza infections.Key Market Challenges
Vaccine Hesitancy and Low Awareness
Despite ongoing public health efforts, vaccine hesitancy remains a key challenge in India’s influenza vaccine market. Unlike childhood immunization, which benefits from widespread awareness and compliance, adult influenza vaccination is often undervalued. Many individuals mistakenly equate influenza with the common cold, underestimating its potential severity and complications. This perception diminishes the urgency to vaccinate, particularly among healthy adults. Additionally, the prevalence of traditional medicine and self-treatment practices further hampers vaccine uptake. Even within the healthcare sector, inconsistent advocacy and limited emphasis on adult flu vaccination contribute to low adoption rates. Addressing these misconceptions through education and awareness campaigns is crucial for improving vaccine coverage across different population segments.Key Market Trends
Technological Advancements in Vaccine Development
Advancements in vaccine development are transforming the influenza vaccine landscape in India. New technologies such as cell-based and recombinant vaccines are improving production timelines and immunogenicity. Unlike conventional egg-based vaccines, which face constraints like allergen risks and longer development cycles, cell-based vaccines offer enhanced scalability and effectiveness. The rise of recombinant vaccines, which bypass the need for live virus cultivation, allows quicker responses to evolving flu strains. Additionally, mRNA-based influenza vaccines - modeled after successful COVID-19 vaccines - are under active research and show promise for higher efficacy, rapid adaptability, and durable protection. These innovations are set to improve public health outcomes while increasing vaccine availability and preparedness during seasonal outbreaks.Key Market Players
- GSK PLC
- Pfizer Inc
- Merck & Co Inc
- Viatris Inc
- AstraZeneca PLC
- Sanofi SA
- Serum Institute of India
- Bharatbiotech International Ltd
Report Scope
In this report, the India Influenza Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.India Influenza Vaccine Market, By Type:
- Inactivated
- Live Attenuated
India Influenza Vaccine Market, By Indication:
- Quadrivalent
- Trivalent
India Influenza Vaccine Market, By Age Group:
- Pediatric
- Adult
India Influenza Vaccine Market, By Route of Administration:
- Injection
- Nasal Spray
India Influenza Vaccine Market, By Distribution Channel:
- Hospitals & Pharmacies
- Government & Institutional Supply
- Others
India Influenza Vaccine Market, By Region:
- East India
- West India
- North India
- South India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the India Influenza Vaccine Market.Available Customizations:
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- GSK PLC
- Pfizer Inc
- Merck & Co Inc
- Viatris Inc
- AstraZeneca PLC
- Sanofi SA
- Serum Institute of India
- Bharatbiotech International Ltd
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 85 |
Published | April 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 26.76 Million |
Forecasted Market Value ( USD | $ 41.28 Million |
Compound Annual Growth Rate | 7.4% |
Regions Covered | India |
No. of Companies Mentioned | 8 |